Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
POW ARCHIVE WEEK: Papers: 28 May 2022 - 3 Jun 2022
DATE PUBLISHED: 2022 May 27
JOURNAL:Cephalalgia
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35633025?dopt=Abstract
CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3 double-blind studies in chronic or episodic cluster headache.